Research Article
Cost-Effectiveness Analysis for the Treatment of Hyperphosphatemia in Predialysis Patients: Calcium-Based versus Noncalcium-Based Phosphate Binders
Table 3
Base case results (3% discount on costs and outcomes).
| | Treatment | Lifetime cost per patient (RM) | Effect (LY) | ICER (Cost per LY gained) | Effect (QALY) | ICER (Cost per QALY gained) |
| | CaCO3 | 77,139 | 4.25 | - | 3.54 | - | | Sevelamer | 159,901 | 6.37 | - | 5.27 | - | | Incremental | 82,763 | 2.12 | 39,050 | 1.74 | 47,679 |
|
|
